Geron reported $534.12M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Amgen USD 92.5B 1.92B Mar/2026
Bio Techne USD 2.55B 27.9M Mar/2026
Cassava Sciences USD 108.37M 9.99M Mar/2026
Cytokinetics USD 1.27B 151.06M Mar/2026
Exelixis USD 2.59B 250.83M Mar/2026
Genmab DKK 12.87B 5.85B Dec/2025
Geron USD 534.12M 36.42M Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Novavax USD 1.04B 133.35M Mar/2026